Alarcon-Segovia D, Ramos-Niembro F, Ibanez de Kasep G, Alcocer J, Tamayo R P
J Rheumatol. 1979 Nov-Dec;6(6):705-12.
Fifteen patients with PSS, 4 with CRST syndrome, and 4 with localized scleroderma have been treated with colchicine at the maximum tolerated individual doses for an average of 39 months (range 19--57). All but 2 of the 19 patients with generalized scleroderma and 3 of those with localized scleroderma improved. Patients who had had scleroderma for less than 5 yr when begun on colchicine, and those who received total doses of colchicine of more than 1,438 mg, scored a significantly higher mean response index than those with longer disease duration, or those who received less colchicine.
15例进行性系统性硬化症患者、4例CRST综合征患者和4例局限性硬皮病患者接受了秋水仙碱治疗，剂量为个体最大耐受量，平均治疗39个月（范围19 - 57个月）。19例全身性硬皮病患者中除2例、局限性硬皮病患者中除3例之外，其余患者病情均有改善。开始使用秋水仙碱时患硬皮病时间不足5年的患者，以及接受秋水仙碱总剂量超过1438毫克的患者，其平均反应指数显著高于病程较长或接受秋水仙碱剂量较少的患者。
